Edesa Biotech EV/EBITDA
Qual é o EV/EBITDA de Edesa Biotech?
O EV/EBITDA de Edesa Biotech, Inc. é N/A
Qual é a definição de EV/EBITDA?
EV/EBITDA é o valor da empresa dividido pelo lucro antes de juros, impostos, depreciação e amortização. É uma medida de quão cara é uma ação e é mais frequentemente válida para comparações entre empresas do que da relação entre preço e lucro. Ele mede o preço (na forma de valor da empresa) que um investidor paga em benefício do fluxo de caixa da empresa (na forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de empresas na Setor Health Care em NASDAQ em comparação com Edesa Biotech
O que Edesa Biotech faz?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Empresas com ev/ebitda semelhantes a Edesa Biotech
- Bambuser AB (publ) tem EV/EBITDA de N/A
- Nevada Metals tem EV/EBITDA de N/A
- Elys Game Technology tem EV/EBITDA de N/A
- Velodyne Lidar tem EV/EBITDA de N/A
- Blue Sky Alternative Investments tem EV/EBITDA de N/A
- Arix Bioscience plc tem EV/EBITDA de N/A
- Edesa Biotech tem EV/EBITDA de N/A
- Shenzhen Neptunus Interlong Bio-technique tem EV/EBITDA de N/A
- Baumot AG tem EV/EBITDA de N/A
- Discovery Harbour Resources tem EV/EBITDA de N/A
- Guardion Health Sciences Inc tem EV/EBITDA de N/A
- Taronis Fuels tem EV/EBITDA de N/A
- DQ Entertainment (International) tem EV/EBITDA de N/A